Breast Cancer

According to findings presented at 2017 ASCO, frontline treatment with ribociclib (Kisqali) plus letrozole improved PFS for patients with HR+/HER2- advanced breast cancer.

The traditional Chinese exercise, tai chi, may assist breast cancer survivors experiencing insomnia.

A form of T-cell (non-Hodgkin) lymphoma known as breast implant associated anaplastic large-cell lymphoma (BIA-ALCL) has been noted as a rare association with the implant-based approach of reconstructive surgery post mastectomy.

Recent changes to FDA labels regarding adverse events.

More Stage I cancers were diagnosed after the passage of the Affordable Care Act (ACA), also known as Obamacare, within five screenable disease types: colorectal cancer, female breast cancer, cervical cancer, lung cancer, and prostate cancer).

Researchers found that tai chi chih, including guided movement and meditation, may be helpful in reducing insomnia experienced by breast cancer survivors.

Examining the experience of 3 women, aged 24 to 28, with stage III breast cancer, oncology nurses from the University of Texas at Austin School of Nursing aimed to gain more insight into the experience of younger woman with breast cancer.

Patricia Jakel, RN, MN, AOCN, ended up on the opposite of the bed than she was used to when she was diagnosed with stage III invasive lobular breast cancer.

The FDA has approved the co-packaging of oral medication ribociclib and letrozole, used to treat HR-positive, HER2-negative advanced breast cancer in postmenopausal women.

Nurses at the Stefanie Spielman Comprehensive Breast Center at the James Cancer Hospital at Ohio State University assessed the treatment standards for patients with breast cancer who are pregnant.

Carolyn Phillips, MSN, RN, ACNP-BC, AOCNP, discusses the unique experienes of young adult patients in their 20x with breast cancer.

Joaimee Cutrone, BSN, RN, discusses the importance of awareness for male breast cancer.

Eric Vachon, BSN, PhD candidate, discusses the importance of taking all variables of complexity into account when considering adherence to kinase inhibitors.

Seven professional organizations came together to issue a new position statment on recommendations for treating patients with aromatase-inhibitor-related bone loss (AIBL).

A recent study indicates that the use of bilateral mastectomy to treat women with ductal carcinoma in situ is unnecessary.

A recent study evaluated the effect of red light on hair growth in women with breast cancer.

Second primary cancers that occur in pediatric, adolescent and young adult (AYA) patients are deadlier than those that occur in older patients.

The Paxman Scalp Cooling System has been granted FDA clearance to reduce hait loss in patients with breast cancer recieving chemotherapy.

An ongoing trial is evaluating the addition of PARP inhibitor velaparib to a chemotherapy combination, for patients with HER2-negative, germline BRCA-associated metastatic or locally advanced breast cancer.

With more patients diagnosed with breast cancer looking to contralateral prophylactic mastectomy, it is important that surgeons discuss this procedure in-depth so patients can better understand.

Language barriers can mean patients put off preventive screenings, and even treatment, for fear of being misunderstood by their healthcare providers.

Thought the incidence of breast cancer has decreased in many US racial/ethnic populations, the rate has increased in the Asian-American population.

Angie Meillier, RN, MS, CPPM, discusses the importance of shared decision making and patient understanding in breast cancer and throughout oncology.

Fewer people are dying from cancer than years ago, according to a recent study.

Expert Adam M. Brufsky, MD, PhD, discusses the considerations for bone-targeted agents denosumab and zoledronic acid (Zometa) in patients with breast cancer.

For patients with breast cancer on aromatase inhibitors, preventive sexual counseling can reduce sexual dysfunction, and it should be provided earlier in treatment, with support from providers.

A recent study evaluated how muscle mass can be used to predict which patients will experience toxicities from chemotherapy and to what extent.

The PARP inhibitor olaparib improved PFS when compared to standard chemotherapy in patients with BRCA-positive breast cancer, according to findings from the phase III OLYMPIAD trial.

The FDA has granted approval to ribociclib (Kisqali) for firstline treatment of HR+/HER2- breast cancer.